Menstruation
PMS & PMDD — References & further reading
References
1 Ginsburg, K., & Dinsay, R. 2000. Premenstrual Syndrome. In: Ransom,
S., ed. Practical Strategies in Obstetrics and Gynecology, (684–694).
Philadelphia: W.B. Saunders Co.
Population Division, US Census Bureau. 06.14.2004. Annual estimates of the population
by sex and five-year age groups for the United States: April 1, 2000 to July 1,
2003 (NC-EST2003-01). URL: http://www.census.gov/popest/national/asrh/NC-EST2003/NC-EST2003-01.pdf
(accessed 01.22.2007).
2 Mishell, D. 2005. Epidemiology and etiology of premenstrual disorders.
Managing the spectrum of premenstrual symptoms: A clinician’s guide
(4–9). San Antonio: Dannemiller foundation/MedPro Communications, Inc.
3American Psychiatric Association. 2000. Diagnostic and Statistical Manual
of Mental Disorders, 4th ed., text revision (771–774). Washington,
DC: American Psychiatric Association.
4Sundstrom, P., et al. 2003. GABA receptors, progesterone and premenstrual
dysphoric disorder. Arch. Women’s Ment. Health, 6(1), 23–41.
Rapkin, A., et al. Progesterone metabolite allopregnanolone in women with premenstrual
syndrome. Obstet. Gynecol. 90(5), 709–714.
5 Akhondzadeh, S., et al. 2001b. Passionflower in the treatment of generalized
anxiety: A pilot double-blind randomized controlled trial with oxazepam. J. Clin.
Pharm. Ther., 26, 363–367.
Dhawan, K., et al. 2001. Anti-anxiety studies on extracts of Passiflora incarnata
Linnaeus. J. Ethnopharmacol., 78 (2–3), 165–170.
Schellenberg, 2001. Treatment for the premenstrual syndrome with agnus castus fruit
extract: Prospective, randomised, placebo controlled study. BMJ, 322,
134–137.
Berger, et al. 2000. Efficacy of Vitex agnus castus L. extract Ze 440 in
patients with pre-menstrual syndrome (PMS). Arch. Gynecol. Obstet, 264,
150–153.
Lauritzen, et al. 1997. Treatment of premenstrual tension syndrome with Vitex agnus
castus: Controlled double-blind study versus pyridoxine. Phytomedicine, 4,
183–189.
Smith, S., et al. 1987. Sex steroid effects on extrahypothalamic CNS. II. Progesterone,
alone and in combination with estrogen, modulates cerebellar responses to amino
acid neurotransmitters. Brain Res., 422 (1), 52–62.
Smith, S., et al. 1987. Progesterone alters GABA and glutamate responsiveness: A
possible mechanism for its anxiolytic action. Brain Res., 400 (2), 353–359.
6 Johnson, S. 2001. The multifaceted and widespread pathology of magnesium
deficiency. Med. Hypotheses, 56 (2), 163– 170.
Walker A., et al. 1998. Magnesium supplementation alleviates premenstrual symptoms
of fluid retention. J. Women’s Health, 7 (9), 1157–1165.
7 Thys-Jacobs, S., et al. 1998. Calcium carbonate and the premenstrual
syndrome: E ffects on premenstrual and menstrual symptoms. Premenstrual Syndrome
Study Group. Am. J. Obstet. Gynecol, 179, 444– 452.
8 Rapkin, A. 2005. New approaches to treating premenstrual disorders.
Managing the spectrum of premenstrual symptoms: A clinician’s guide.(15–
22). San Antonio: Dannemiller foundation/MedPro Communications, Inc
9 Steege J.,& Blumenthal, J. 1993. The effects of aerobic exercise
on premenstrual symptoms in middle-aged women: A preliminary study. J. Psychosom.
Res., 37 (2),127– 133.
Further Reading
Lee, J. 1999. What Your Doctor May Not Tell You about Premenopause. NY:
Warner Books.
Ross, J. 2002. The Mood Cure. NY: Penguin Books.
Return to:
Understanding PMS and PMDD
Original Publication Date: 1/29/2007
Last Modified:
02/16/2010
Principal Author: Amy Amoroso